このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

治癒困難な創傷における抵抗性容量性電気伝達療法の効果

治癒困難な創傷における創傷治癒およびバイオマーカー発現に対する抵抗性容量性電気伝達療法の効果

Difficult-to-heal wounds present imbalances in cytokine production, increases in MMP expression, high levels of apoptosis, and decreases in the proliferation of cells such as fibroblasts and keratinocytes, which are involved in tissue regeneration. CRET therapy (capacitive resistive electrical transfer therapy) has been shown to generate granulation tissue in in vitro assays. In addition, available clinical case reports and preliminary clinical trial results indicate that CRET can promote the regeneration of acute wounds and DHW (difficult-to-heal wounds).

調査の概要

詳細な説明

Difficult-to-heal wounds present imbalances in cytokine production, increases in MMP expression, high levels of apoptosis, and decreases in the proliferation of cells such as fibroblasts and keratinocytes, which are involved in tissue regeneration. CRET therapy has been shown to be able to generate granulation tissue in in vitro assays. In addition, available clinical case reports and preliminary clinical trial results indicate that CRET can promote acute wound regeneration and CDH.

The working hypothesis is that CRET treatment promotes the healing of CDH through its action in regulating inflammatory and regenerative processes in skin tissue. This non-invasive, cost-effective treatment, devoid of identified adverse effects, and not studied in depth so far in patients with CDH, can thus be placed in the treatment algorithms of CDH with the correct selection of candidate patients.

研究の種類

介入

入学 (推定)

137

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • Madrid
      • Madrid、Madrid、スペイン、28034
        • 募集
        • Hospital Ramón y Cajal
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • 18 years of age or older

  • Agree to participate in the study and sign the informed consent form.

  • Inpatients or outpatients who can be followed by the research team for the duration of the study

  • Ulcers with a surface area of no less than 0.5 cm2 and of at least 4 weeks' duration (CDH), located on the lower limbs in the case of ulcers of venous etiology or on the foot, in the case of diabetic foot ulcers.

  • For patients with ulcers of venous etiology: ulcers of venous etiology stage 2, 3 4 with diagnosis of chronic venous insufficiency with open wound CEAP IVC C6 according to CEAP classification (38).

  • For patients with diabetic foot ulcers presenting:

    • Type 1 and type 2 diabetics with a glycated hemoglobin (HbA1c ≤10% (in a test no longer than 3 months).
    • Patients with UPD without PAD or with associated mild or moderate stage PAD (39) according to the criteria of the intersociety consensus for the treatment of peripheral arterial disease (TASC II).
    • UPD Grade 1A, 1C, 2A, 2C according to the Texas classification (40).
    • Patients who have required previous surgical debridement and 4 weeks have elapsed since such debridement.
  • Comorbidity is defined as the presence of at least one of the following criteria:

    • Smoking more than 10 cigarettes per day in the last 6 months.
    • Immunosuppression: systemic treatment with high-dose corticosteroids in the previous 3 months, severe active infection in the previous month, presence of systemic or organ-specific autoimmune disease.
    • Renal failure with creatinine > 2 mg/dl.
    • Respiratory failure with pO2< 90 mm Hg
    • Cardiac failure, grade II or higher
    • Anemia or nutritional deficit
    • Endocrine disruption under medical treatment
    • Neuropathy in the affected area or neurological disease.
    • Connective tissue diseases
    • Mobility impairment
    • Presence of microvascular disease

Exclusion Criteria:

  • Pregnancy
  • Patients with contraindications for CRET treatments (electronic implants, thrombophlebitis).
  • Patients with chronic or pathological wounds that required surgical intervention.
  • Ulcers with active infection according to IDSA classification in soft tissues or with clinical and/or radiological signs compatible with osteomyelitis.
  • Allergies to standard wound treatment.
  • Patients presenting severe renal insufficiency (Glomerular filtration rate ≤30 ml/min in analysis performed in the last 3 months).
  • Patient who has presented an acute ischemic event (acute myocardial infarction or stroke, in the 3 months prior to inclusion in the study).
  • Patients who present an evolving neoplastic condition, treated by radiotherapy, chemotherapy, hormone therapy or immunosuppressants at the current moment.
  • Patients treated for a chronic condition requiring the intake of strong systemic corticosteroids doses ≥ 40 mg prednisone).
  • Critical non-revascularizable ischemia or TcPO2 < 25mmHg or a digital hallux systolic pressure < 50 mm Hg in diabetic foot ulcers.
  • Patients who do not accept to use the prescribed unloading treatment in the case of diabetic foot ulcers.
  • In the case of patients with ulcers of venous etiology, the presence of peripheral arterial disease in any of its stages.
  • Patients who do not accept the indicated compressive bandage treatment, in the case of ulcers of venous etiology.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:支持療法
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:A-E group

Treatment with radiofrequency currents of resistive capacitive electrical transfer therapy (CRET) under hyperthermia conditions plus standard clinical treatments, in patients with ulcers of venous etiology.

Static Monopolar Capacitive Resistive Resistive Radiofrequency Equipment at 448 kHz

standard clinical procedures

実験的:B-E group

Treatment with radiofrequency currents of resistive capacitive electrical transfer therapy (CRET) under hyperthermia conditions plus standard clinical treatments in patients with diabetic foot ulcers.

Static Monopolar Capacitive Resistive Resistive Radiofrequency Equipment at 448 kHz

standard clinical procedures

実験的:A-C grouop

Treatment with radiofrequency currents of resistive capacitive electrical transfer therapy (CRET) under hyperthermia conditions plus standard clinical treatments in CDH.

Static Monopolar Capacitive Resistive Resistive Radiofrequency Equipment at 448 kHz

standard clinical procedures

実験的:B-C grouop

Treatment with radiofrequency currents of resistive capacitive electrical transfer therapy (CRET) under subthermal conditions plus standard clinical treatments in CDH.

Static Monopolar Capacitive Resistive Resistive Radiofrequency Equipment at 448 kHz

standard clinical procedures

実験的:C-C group

Standard clinical treatments established on the basis of the treatment standards of the International Working Group on the Diabetic Foot (IWGDF), in the case of diabetic foot ulcers (2, 3). For ulcers of venous etiology, the treatment standards according to the guidelines of the Spanish Association of Vascular Nursing and Wounds (Asociación Española de Enfermería Vascular y Heridas) will also be applied.

standard clinical procedures

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Wound dimensions before and after treatments in patients with HDC treated with CRET therapy plus standard treatment versus patients with HDC undergoing standard treatment alone.
時間枠:18 months

Wound dimensions measurement (area, length and width) before and after treatments in patients with HDC treated with CRET therapy plus standard treatment versus patients with HDC undergoing standard treatment alone.

18 months

二次結果の測定

結果測定
メジャーの説明
時間枠
General clinical evaluation:
時間枠:18 months
  • age,
  • sex,
  • BMI
  • general medical history,
  • baseline blood work,
  • usual treatment
18 months
Wound evaluation:
時間枠:18 months
  • cause,
  • location,
  • time of evolution,
  • photographs.
18 months
Evaluation of biomarkers in peripheral blood of patients with CDH with or without CRET treatment:
時間枠:18 months

Quantification of cytokines and growth factors: IL-1α, IL-1β, TNFα, IFγ.

18 months
In primary cultures of fibroblasts isolated from biopsies of CDH patients with or without CRET treatment, assessment of typical CDH biomarkers related to:
時間枠:18 months
  • Death: TUNEL assay; Bcl-2, Bcl-X and Caspase-3 markers.
  • Viability/proliferation: XTT, Ki67, p-p38 and p-ERK1/2 assays.
  • Adhesion: β -catenin and E-cadherin.
  • Extracellular matrix: α-SMA, Col I and Col III and the metalloproteinases, MMP8, MMP2 and MMP9.
18 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Maria Luisa Hernández Bule, PhD、IRYCIS. Hospital Universitario Ramón y Cajal. Madrid, Spain.

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年1月31日

一次修了 (実際)

2024年7月31日

研究の完了 (推定)

2027年6月1日

試験登録日

最初に提出

2023年6月29日

QC基準を満たした最初の提出物

2023年7月18日

最初の投稿 (実際)

2023年7月20日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月6日

QC基準を満たした最後の更新が送信されました

2026年11月3日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • CRET-ÚLCERAS-01

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する